hrp0089p3-p309 | Pituitary, Neuroendocrinology and Puberty P3 | ESPE2018

GLP-1 Receptor Agonist in a Patient with Craniopharyngioma-Related Obesity

Antoniou Maria-Christina , Diaz-Escagedo Patricia , Bouthors Therese , Elowe-Gruau Eglantine , Stoppa-Vaucher Sophie , Messerer Mahmoud , Hauschild Michael

Introduction: Glucagon-like peptide 1 (GLP-1) receptor agonists have been successfully used in adults with hypothalamic obesity, showing a BMI decrease and metabolic profile improvement. Data on GLP-1 receptor agonist treatment for children and adolescents is limited. Herein, we present a clinical case of a male adolescent treated with GLP-1 receptor agonist for hypothalamic obesity, secondary to craniopharyngioma.Case report: A 15.8 year-old boy (Height...

hrp0089p1-p083 | Diabetes & Insulin P1 | ESPE2018

HERV-W-Env Protein Expression in Pediatric Type 1 Diabetes Patients

Bouthors Therese , Elowe-Gruau Eglantine , Diaz-Escagedo Patricia , Antoniou Maria-Christina , Stoppa-Vaucher Sophie , Levet Sandrine , Medina Julie , Demolder Amandine , Perron Herve , Hauschild Michael

Introduction: The envelope protein of Human Endogenous Retrovirus type W (HERV-W-Env) has been shown to be associated with type 1 diabetes (T1D) pathogenesis in adults patients. This protein is expressed in pancreas of T1D patients and it seems to correlate with macrophage infiltrations. In vitro and in vivo studies have demonstrated that HERV-W-Env inhibits insulin secretion and promotes hyperglycemia. Furthermore, HERV could be implicated in other auto-immune disorders. The ...

hrp0094fc6.1 | Bone and Mineral Metabolism | ESPE2021

Evaluation of the potential benefits of biphosphonate treatment on symptomatic vertebral fractures in children treated for acute lymphoblastic leukemia

Diaz Escagedo Patricia , Fiscaletti Melissa , Di Ioia Rose , Perrault Melissa , Olivier Patricia , Dubois Josee , Miron Marie-Claude , Laverdiere Caroline , Hoa Tran Thai , Alos Nathalie ,

Background and Aim: Vertebral fractures (VF) in children with acute lymphoblastic leukemia (ALL) are often symptomatic and impairing life quality. Prevalence of children with VF at ALL diagnosis has been reported as 16% with peak incidence occurring during the first year after diagnosis and a 6-year cumulative incidence of 32.5%. Moreover, only 15.8% of these patients will have vertebral reshaping 24 months after ALL diagnosis. Additionally, 23% of ALL survivo...